Income statement
CAD
Annual
| Metric | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|
| Revenue | 27M | 13M | 13M | 0 |
| Gross Profit | 15M | 9M | 9M | 0 |
| Operating Income | -22M | -7M | -9M | -218K |
| EBITDA | -16M | -11M | -8M | -2K |
| Net Income | -14M | -9M | -11M | -218K |
| EPS (Diluted) | — | — | — | — |
Healthcare
Live Price
Offline$0.0001
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 → Jun 11, 2026
Coverage: 244 bars · Jun 23, 2025 → Jun 11, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Skylight Health Group Inc. (SLHPF) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 23, 2025 → Jun 11, 2026). Baseline metrics include revenue growth of +106.7%, EPS growth of +14.0%, a dividend yield of 0.0%. What stands out right now is revenue +106.7%, EPS +14.0%, free cash flow -354.1% with operating margin -75.3% and ROIC -25.9%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines SLHPF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SLHPF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SLHPF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SLHPF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
-100.0% YoY
FY Net Income
-$218.3K
+98.0% YoY
Free Cash Flow
-$97.3K
+95.7% YoY
Revenue Growth
+106.7%
EPS Growth
+14.0%
Gross Margin
55.6%
Net Margin
-57.7%
Income statement
CAD
| Metric | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|
| Revenue | 27M | 13M | 13M | 0 |
| Gross Profit | 15M | 9M | 9M | 0 |
| Operating Income | -22M | -7M | -9M | -218K |
| EBITDA | -16M | -11M | -8M | -2K |
| Net Income | -14M | -9M | -11M | -218K |
| EPS (Diluted) | — | — | — | — |
Balance sheet
CAD
| Metric | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|
| Cash & Equivalents | 12M | 20M | 130K | 28K |
| Total Assets | 65M | 31M | 9M | 84K |
| Total Liabilities | 27M | 4M | 8M | 120K |
| Shareholder Equity | 38M | 28M | 1M | -36K |
| Total Debt | 16M | 2M | 6M | 50K |
| Net Debt | 5M | -18M | 6M | 22K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
97K
+91.5% YoY
Capital Expenditures
0
+100.0% YoY
Free Cash Flow
97K
+95.7% YoY
Key ratios
Gross Margin
55.6%
Operating Margin
-75.3%
Net Margin
-57.7%
ROE
-47.8%
Debt / Equity
0.43x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.